2009 (English)In: New England Journal of Medicine, ISSN 0028-4793, Vol. 361, no 8, 826-827 p.Article in journal, Letter (Refereed) Published
In their review article on scleroderma, Gabrielli et al. incorporate their earlier observations that all patients with this disease have activating antibodies to platelet-derived growth factor (PDGF) receptors (PDGFRs). These antibodies were described as being specific for scleroderma and for chronic extensive graft-versus-host disease, two conditions that share some clinical features. The review does not reflect the current debate on the existence of such antibodies. Researchers from several centers, including ours, have challenged the results of Gabrielli et al.
Place, publisher, year, edition, pages
2009. Vol. 361, no 8, 826-827 p.
Scleroderma, PDGF, autoantibodies
Research subject Medicine
IdentifiersURN: urn:nbn:se:uu:diva-124931DOI: 10.1056/NEJMc091209ISI: 000269081200023PubMedID: 19692697OAI: oai:DiVA.org:uu-124931DiVA: diva2:318184